Genprex (NASDAQ: GNPX)
$2.50
(-2.5%)
-$0.06
Price as of May 15, 2024, 3:58 p.m. ET
Genprex Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Genprex Company Info
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company’s lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.